Market news — every asset we track

Assets

EXAS

Abbott investigates two separate cyber incidents, says no operations affected

Jul 17ReutersEXAS

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Jul 17The Globe and MailEXAS

Abbott raises 2026 profit forecast on strength in diagnostics, heart devices

July 16 () - Abbott beat estimates for quarterly results and raised its annual profit forecast on Thursday, ‌banking on strong demand for its newly acquired ‌cancer diagnostics business, sending its shares up nearly 4% premarket. Abbott said its cancer diagnostics business, which now includes recently acquired Exact Sciences' flagship colorectal cancer screening test, Cologuard, and breast cancer assay Oncotype DX, is helping offset ongoing declines in ‌revenue from COVID-19 testing ⁠products.

Jul 16Yahoo FinanceEXAS

ABT

Abbott Q2 2026 earnings beat, raises full-year profit guidance

The healthcare company posted adjusted earnings of $1.31 a share in the second quarter, topping Wall Street's estimate of $1.28

Jul 16Yahoo FinanceEXAS

ABT

Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition

Jul 15Seeking AlphaEXAS

ABT

This is the newest page. Registered accounts read further back.